H.C. Wainwright lowered the firm’s price target on Transcode Therapeutics (RNAZ) to $10 from $20 and keeps a Buy rating on the shares. The firm updated the company’s model following the release of its annual filing. It cites Transcode’s latest equity raises for the target cut and assumes the company’s current cash and equivalents following the raise are sufficient to fund operations into 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- TransCode Therapeutics Delays Annual Report Filing
- Transcode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trial
- RNAZ Upcoming Earnings Report: What to Expect?
- Biotech Alert: Searches spiking for these stocks today
- Transcode to sell 10.25M shares at 98c per share in registered direct offering
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue